



## Final Appraisal Recommendation

### Rosuvastatin (Crestor<sup>®</sup>)

Submission by:  
AstraZeneca UK Ltd

Advice No: 1311 – November 2011

#### Recommendation of AWMSG

Rosuvastatin (Crestor<sup>®</sup>) is not recommended for use within NHS Wales for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

The clinical and cost effectiveness evidence provided was not sufficient for AWMSG to recommend its use.

#### Additional notes:

Patients who are currently being treated with rosuvastatin (Crestor<sup>®</sup>) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching this recommendation AWMSG took account of the [AWMSG Secretariat Assessment Report](#), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, [clinical expert opinion](#), lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: